These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34593171)

  • 21. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the medical loss ratio a good target measure for regulation in the individual market for health insurance?
    Karaca-Mandic P; Abraham JM; Simon K
    Health Econ; 2015 Jan; 24(1):55-74. PubMed ID: 24123608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness research as choice architecture: the behavioral law and economics solution to the health care cost crisis.
    Korobkin R
    Mich Law Rev; 2014 Feb; 112(4):523-74. PubMed ID: 24446572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can ICER bring cost-effectiveness to drug prices?
    Butcher L
    Manag Care; 2019 Jun; 28(6):30-33. PubMed ID: 31188097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are Health Insurance Markets Competitive?
    Dafny LS
    Am Econ Rev; 2010 Sep; 100(4):1399-431. PubMed ID: 29517879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D.
    Sanzenbacher GT; Wettstein G
    J Health Econ; 2020 Jul; 72():102332. PubMed ID: 32416367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug prices, out-of-pocket payments, and insurer costs: how do payers vary?
    Chen J; Rizzo JA
    Adv Health Econ Health Serv Res; 2010; 22():221-31. PubMed ID: 20575235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Approaches to Drug Pricing.
    Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
    Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions.
    Vernon JA; Hughen WK; Johnson SJ
    Health Care Manag Sci; 2005 May; 8(2):167-79. PubMed ID: 15952613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.